Condition: NSCLC · Sponsor: Guangdong Association of Clinical Trials
This is a single-center, open-label, investigator-initiated clinical trial. It aims to evaluate the safety and tolerability of RGL-270 in combination with a PD-1/PD-L1 inhibitor, to assess immunogenicity, preliminary efficacy, and exploratory biomarkers and to observe the safety and effectiveness of PD-1/PD-L1 inhibitor monotherapy in advanced NSCLC subjects through a real-world observational cohort.
This description comes directly from the study's public registry record.
Wang Hao · hao.wang@regenelead.com
Xiaojun Tan · xiaojun.tan@regenelead.com
Always discuss trial participation with your own doctor first.
| Guangdong Provincial Perople's Hospital | Guangzhou, Other (Non U.s.), China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07652125